PoC(Point-of-Care) 결핵(TB) 초고감도 핵산 증폭 검사(NAAT) 시장 보고서(2026년)

A point-of-care tuberculosis ultra-sensitive nucleic acid amplification test is a rapid molecular diagnostic tool developed to detect Mycobacterium tuberculosis genetic material near or at the patient's care setting. Using advanced amplification methods, it identifies very low bacterial loads with high sensitivity and specificity, enabling early and reliable diagnosis. Designed to be compact and automated, this test delivers fast results, supporting timely clinical decisions and effective disease management.

The key technologies of point-of-care tuberculosis ultra-sensitive nucleic acid amplification tests include polymerase chain reaction (PCR)-based nucleic acid amplification testing, isothermal amplification, and other methods. PCR-based nucleic acid amplification testing is a molecular technique that rapidly amplifies and detects specific DNA or RNA sequences to identify pathogens with high sensitivity. Product types include instruments, reagents and consumables, and software, and testing is performed on samples such as sputum, blood, urine, and others. End users include hospitals and clinics, diagnostic laboratories, research institutes, and other organizations.

Tariffs have affected the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market by increasing the cost of importing high-precision instruments, reagents, and consumables. This impact is most pronounced in regions such as North America and Europe, which rely on imports for advanced diagnostic devices. While tariffs have slowed procurement and adoption in some healthcare facilities, they have also encouraged local manufacturing, innovation in cost-efficient solutions, and diversification of supply chains, ultimately enhancing market resilience.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market research report is one of a series of new reports from The Business Research Company that provides point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market statistics, including point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) industry global market size, regional shares, competitors with a point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market share, detailed point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market segments, market trends and opportunities, and any further data you may need to thrive in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) industry. This point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market size has grown rapidly in recent years. It will grow from $0.88 billion in 2025 to $1 billion in 2026 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be attributed to rising tuberculosis prevalence, adoption of conventional molecular diagnostics, increasing government health initiatives, expansion of hospital networks, growing awareness of early diagnosis benefits.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to demand for ultra-sensitive point-of-care testing, integration of ai with diagnostic assays, expansion of decentralized healthcare, investment in rapid nucleic acid amplification technologies, increasing funding for tuberculosis control programs. Major trends in the forecast period include rapid point-of-care testing, ultra-sensitive nucleic acid amplification, automated diagnostic platforms, compact & portable test devices, integration with electronic health records.

The increasing prevalence of infectious diseases is anticipated to drive the growth of the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market in the coming years. Infectious diseases are conditions caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that can spread directly or indirectly among individuals. The growing prevalence of infectious diseases is fueled by rising global population density, which heightens transmission risks and facilitates disease spread. Point-of-care tuberculosis ultra-sensitive nucleic acid amplification testing addresses the increasing prevalence of infectious diseases by providing rapid, highly sensitive, and decentralized detection of infectious pathogens, thereby enhancing early diagnosis and disease control measures. For example, in March 2025, the UK Health Security Agency, a UK-based government health authority, reported that tuberculosis cases in England rose by 13% in 2024, reaching 5,480 cases compared to 4,850 cases in 2023. Consequently, the growing prevalence of infectious diseases is propelling the expansion of the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market.

Leading companies operating in the point-of-care tuberculosis ultra-sensitive nucleic acid amplification test (NAAT) market are focusing on regulatory validation and international prequalification programs to enhance quality assurance, accelerate global adoption, and improve access to high-sensitivity diagnostic solutions. Prequalification refers to a regulatory assessment process that evaluates in vitro diagnostic products for compliance with international standards of quality, safety, and performance, enabling procurement by global health agencies and deployment in resource-limited settings. For example, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, announced the first prequalification of an Xpert MTB/RIF, an ultra-tuberculosis diagnostic test, under its regulatory assessment framework. This milestone supports the expansion of reliable and rapid TB detection tools, particularly across low- and middle-income countries. Leveraging advanced nucleic acid amplification technology, cartridge-based automated systems, and rapid result turnaround capabilities, the solution facilitates decentralized testing, improves early case detection, and strengthens drug-resistance identification. It is specifically engineered for deployment in primary healthcare facilities and remote regions with limited laboratory infrastructure, thereby enhancing surveillance capacity, reducing diagnostic delays, and supporting global tuberculosis control and antimicrobial resistance management initiatives.

In March 2023, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, a Switzerland-based government agency; the United States Agency for International Development (USAID), a US-based government agency; and Stop TB, a Switzerland-based non-profit organization, announced a partnership with Molbio Diagnostics Pvt. Ltd. to expand global access to rapid molecular diagnostic tests for tuberculosis. Through this partnership, the organizations aim to increase the availability of point-of-care, ultra-sensitive nucleic acid amplification tests (NAATs) for TB detection, especially in high-burden and resource-limited regions, thereby enhancing early diagnosis and treatment initiation efforts globally. Molbio Diagnostics Pvt. Ltd. is an India-based manufacturer of portable, cartridge-based molecular platforms (such as Truenat) engineered for rapid, near-patient TB detection using nucleic acid amplification technology.

Major companies operating in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, QIAGEN N.V., SD BIOSENSOR Inc., Eiken Chemical Co. Ltd, Oxford Nanopore Technologies Ltd, Molbio Diagnostics Limited, Sansure Biotech Inc., CapitalBio Corporation, QuantuMDx Group Limited, Tata Medical Diagnostics Limited, Ustar Biotechnologies, Mylab Discovery Solutions Private Limited, GenoScreen SAS, Co-Diagnostics Inc., Longhorn Vaccines Diagnostics LLC, Akonni Biosystems Inc., Zeesan Biotech Co. Ltd, Redcliffe labs.

North America was the largest region in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market consists of revenues earned by entities by providing services such as regulatory compliance support services, distribution and logistics services, and after-sales support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market also includes sales of disposable pipette tips, microfluidic chips, control materials, and calibration kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses point of care (poc) tuberculosis (tb) ultra-sensitive nucleic acid amplification test (naat) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for point of care (poc) tuberculosis (tb) ultra-sensitive nucleic acid amplification test (naat) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The point of care (poc) tuberculosis (tb) ultra-sensitive nucleic acid amplification test (naat) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Technology: Polymerase Chain Reaction Based Nucleic Acid Amplification Testing; Isothermal Amplification; Other Technologies
• 2) By Product Type: Instruments; Reagents And Consumables; Software
• 3) By Sample Type: Sputum; Blood; Urine; Other Sample Types
• 4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
• Subsegments:
• 1) By Polymerase Chain Reaction Based Nucleic Acid Amplification Testing: Real Time Polymerase Chain Reaction; Digital Polymerase Chain Reaction; Multiplex Polymerase Chain Reaction; Nested Polymerase Chain Reaction
• 2) By Isothermal Amplification: Loop Mediated Isothermal Amplification; Recombinase Polymerase Amplification; Nucleic Acid Sequence Based Amplification; Strand Displacement Amplification
• 3) By Other Technologies: Transcription Mediated Amplification; Helicase Dependent Amplification; Rolling Circle Amplification; Branched DNA Amplification
• Companies Mentioned: F. Hoffmann-La Roche AG; Abbott Laboratories; Danaher Corporation; QIAGEN N.V.; SD BIOSENSOR Inc.; Eiken Chemical Co. Ltd; Oxford Nanopore Technologies Ltd; Molbio Diagnostics Limited; Sansure Biotech Inc.; CapitalBio Corporation; QuantuMDx Group Limited; Tata Medical Diagnostics Limited; Ustar Biotechnologies; Mylab Discovery Solutions Private Limited; GenoScreen SAS; Co-Diagnostics Inc.; Longhorn Vaccines Diagnostics LLC; Akonni Biosystems Inc.; Zeesan Biotech Co. Ltd; Redcliffe labs.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Artificial Intelligence & Autonomous Intelligence
• 4.2. Major Trends
  • 4.2.1 Rapid Point-Of-Care Testing
  • 4.2.2 Ultra-Sensitive Nucleic Acid Amplification
  • 4.2.3 Automated Diagnostic Platforms
  • 4.2.4 Compact & Portable Test Devices
  • 4.2.5 Integration With Electronic Health Records

5. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Analysis Of End Use Industries

• 5.1 Hospitals And Clinics
• 5.2 Diagnostic Laboratories
• 5.3 Research Institutes
• 5.4 Community Health Centers
• 5.5 Mobile Health Units

6. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Segmentation

• 9.1. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Polymerase Chain Reaction Based Nucleic Acid Amplification Testing, Isothermal Amplification, Other Technologies
• 9.2. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Product Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Instruments, Reagents And Consumables, Software
• 9.3. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Sputum, Blood, Urine, Other Sample Types
• 9.4. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals And Clinics, Diagnostic Laboratories, Research Institutes, Other End Users
• 9.5. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Sub-Segmentation Of Polymerase Chain Reaction Based Nucleic Acid Amplification Testing, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Real Time Polymerase Chain Reaction, Digital Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Nested Polymerase Chain Reaction
• 9.6. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Sub-Segmentation Of Isothermal Amplification, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Loop Mediated Isothermal Amplification, Recombinase Polymerase Amplification, Nucleic Acid Sequence Based Amplification, Strand Displacement Amplification
• 9.7. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Sub-Segmentation Of Other Technologies, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Transcription Mediated Amplification, Helicase Dependent Amplification, Rolling Circle Amplification, Branched DNA Amplification

10. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Regional And Country Analysis

• 10.1. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 11.1. Asia-Pacific Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 12.1. China Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 13.1. India Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 14.1. Japan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 15.1. Australia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 16.1. Indonesia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 17.1. South Korea Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 18.1. Taiwan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 19.1. South East Asia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 20.1. Western Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 21.1. UK Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 22.1. Germany Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 23.1. France Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 24.1. Italy Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 25.1. Spain Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 26.1. Eastern Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 27.1. Russia Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 28.1. North America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 29.1. USA Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 30.1. Canada Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 31.1. South America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 32.1. Brazil Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 33.1. Middle East Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

• 34.1. Africa Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market, Segmentation By Technology, Segmentation By Product Type, Segmentation By Sample Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Regulatory and Investment Landscape

36. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Competitive Landscape And Company Profiles

• 36.1. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Danaher Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. QIAGEN N.V. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. SD BIOSENSOR Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Other Major And Innovative Companies

• Eiken Chemical Co. Ltd, Oxford Nanopore Technologies Ltd, Molbio Diagnostics Limited, Sansure Biotech Inc., CapitalBio Corporation, QuantuMDx Group Limited, Tata Medical Diagnostics Limited, Ustar Biotechnologies, Mylab Discovery Solutions Private Limited, GenoScreen SAS, Co-Diagnostics Inc., Longhorn Vaccines Diagnostics LLC, Akonni Biosystems Inc., Zeesan Biotech Co. Ltd, Redcliffe labs

38. Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

41. Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market High Potential Countries, Segments and Strategies

• 41.1 Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer